DNA methylation, methylome, cancer, biomarkers, liquid biopsies
cancer cell lines, patient samples
methylome sequencing, state-of-the-art droplet digital methylation specific PCR, qMSP, pyrosequencing, standardized analyses of liquid biopsies
We collaborate with medical doctors (Pathology, Urology, Oncology) within all cancer types studied (colorectal cancer, bladder cancer, cholangiocarcinomas and esophageal cancer), with technologists (methylome sequencing), with a technology transfer office (Inven2; innovation) and commercial companies (biomarker development).
Identification and development of epigenetic biomarkers for early non-invasive detection and monitoring of various cancer types, including bladder cancer, colorectal cancer and cholangiocarcinoma. Several of the biomarkers are covered by patent applications (nine patents are granted). We also aim at analysing and understanding the underlying biology of the biomarkers and how they affect the cancer development. We investigate cancer related defects of the DNA methylation machinery and finally aim at using epigenetics to subclassify cancers.
Founding member of the Young Academy of Norway (http://akademietforyngreforskere.no/en/) NEEDS: Liquid biopsy analyses are increasingly relevant, both in early detection and monitoring of disease, but also for evaluating therapeutic response etc. Highly standardized and highly accurate methods are required for successful liquid biopsy analyses. We have optimized the powerful, and absolute quantitative droplet digital PCR technology for highly standardized DNA methylation analyses of liquid biopsies. Omics analyses such as methylome sequencing are valuable for identification of differentially methylated regions, including potential biomarkers for disease, and should be useful for the Network.